Home > Compound List > Product Information
Degarelix_Molecular_structure_CAS_214766-78-6)
Click picture or here to close

Degarelix

Catalog No. DB06699 Name DrugBank
CAS Number 214766-78-6 Website http://www.ualberta.ca/
M. F. C82H103ClN18O16 Telephone (780) 492-3111
M. W. 1632.25922 Fax (780) 492-1071
Purity Email david.wishart@ualberta.ca
Storage Chembase ID: 4437

SYNONYMS

IUPAC name
(4R)-N-{4-[(2S)-2-{[(1R)-2-[4-(carbamoylamino)phenyl]-1-{[(1S)-1-{[(2S)-1-(2-{[(1R)-1-carbamoylethyl]carbamoyl}pyrrolidin-1-yl)-1-oxo-6-[(propan-2-yl)amino]hexan-2-yl]carbamoyl}-3-methylbutyl]carbamoyl}ethyl]carbamoyl}-2-[(2S)-2-[(2R)-2-[(2R)-3-(4-chlorophenyl)-2-[(2R)-2-acetamido-3-(naphthalen-2-yl)propanamido]propanamido]-3-(pyridin-3-yl)propanamido]-3-hydroxypropanamido]ethyl]phenyl}-2,6-dioxo-1,3-diazinane-4-carboxamide
IUPAC Traditional name
(4R)-N-{4-[(2S)-2-{[(1R)-2-[4-(carbamoylamino)phenyl]-1-{[(1S)-1-{[(2S)-1-(2-{[(1R)-1-carbamoylethyl]carbamoyl}pyrrolidin-1-yl)-6-(isopropylamino)-1-oxohexan-2-yl]carbamoyl}-3-methylbutyl]carbamoyl}ethyl]carbamoyl}-2-[(2S)-2-[(2R)-2-[(2R)-3-(4-chlorophenyl)-2-[(2R)-2-acetamido-3-(naphthalen-2-yl)propanamido]propanamido]-3-(pyridin-3-yl)propanamido]-3-hydroxypropanamido]ethyl]phenyl}-2,6-dioxo-1,3-diazinane-4-carboxamide
Brand Name
Firmagon

DATABASE IDS

PubChem CID 44151801
PubChem SID 99443253
CAS Number 214766-78-6

PROPERTIES

DETAILS

Description (English)
Item Information
Drug Groups approved
Description Degarelix is used for the treatment of advanced prostate cancer. Degarelix is a synthetic peptide derivative drug which binds to gonadotropin-releasing hormone(GnRH) receptors in the pituitary gland and blocks their interaction with GnRH. This antagonism reduces luteinising hormone (LH), follicle-stimulating hormone (FSH) and in turn, testosterone suppression. Reduction in testosterone is important in treating men with advanced prostate cancer.
Indication Degaralix is used for the management of advanced prostate cancer. Its action ultimately results in a reduction in circulating androgens, which provides a therapeutic benefit by reducing the growth stimulus used by hormone-sensitive malignant prostate tissue.
Pharmacology Degarelix is a synthetic derivative of GnRH decapeptide which normally stimulates the GnRH receptor. Gonadotropin and androgen production result from the binding of endogenous GnRH to the GnRH receptor. The ability of Degarelix to antagonize GnRH at its receptor and suppress the release of these hormones is what gives it potency in slowing advanced prostate cancer.
Degarelix antagonizes the GnRH receptor which in turn blocks the release of LH and FSH from the pituitary. The reduction in LH leads to a decrease in testosterone release from the testes and subsequently reduces the size and growth of the prostate cancer.
Affected Organisms
Humans and other mammals
Biotransformation Degarelix is subject to peptide hydrolysis during its passage through the hepatobiliary system and is mainly excreted as peptide fragments in feces. Approximately 20-30% of a given dose of degarelix is renally eliminated, suggesting that approximately 70-80% is excreted via the hepatobiliary system.
Absorption Degarelix forms a depot at the site of injection after subcutaneous administration from which the drug slowly released into circulation. Peak plasma concentrations of degarelix generally occur within 2 days following subcutaneous administration of a single 240-mg dose at a concentration of 40 mg/mL.
Half Life 23-61 days
Protein Binding 90% of the drug is bound to plasma proteins.
References
Steinberg M: Degarelix: a gonadotropin-releasing hormone antagonist for the management of prostate cancer. Clin Ther. 2009;31 Pt 2:2312-31. [Pubmed]
Persson BE, Kold Olesen T, Jensen JK: Degarelix: a new approach for the treatment of prostate cancer. Neuroendocrinology. 2009;90(3):235-44. Epub 2009 Jul 14. [Pubmed]
External Links
Wikipedia

REFERENCES

  • Steinberg M: Degarelix: a gonadotropin-releasing hormone antagonist for the management of prostate cancer. Clin Ther. 2009;31 Pt 2:2312-31. Pubmed
  • Persson BE, Kold Olesen T, Jensen JK: Degarelix: a new approach for the treatment of prostate cancer. Neuroendocrinology. 2009;90(3):235-44. Epub 2009 Jul 14. Pubmed